Top Page
Turn Therapeutics Inc
(NASDAQ:TTRX)
Turn Therapeutics Inc (TTRX) vs. SPDR S&P 500 ETF (SPY)
Turn Therapeutics Inc Business Overview & Revenue Model
Turn Therapeutics Inc Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 |
|---|---|---|
Income Statement | ||
| Total Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| EBITDA | -1.75M | -2.26M |
| Net Income | -1.77M | -2.29M |
Balance Sheet | ||
| Total Assets | 2.05M | 2.01M |
| Cash, Cash Equivalents and Short-Term Investments | 872.60K | 1.18M |
| Total Debt | 121.04K | 25.16K |
| Total Liabilities | 2.23M | 1.93M |
| Stockholders Equity | -177.43K | 85.77K |
Cash Flow | ||
| Free Cash Flow | -1.46M | -1.42M |
| Operating Cash Flow | -1.36M | -1.38M |
| Investing Cash Flow | -99.47K | -44.31K |
| Financing Cash Flow | 1.15M | 500.00K |
Turn Therapeutics Inc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $139.57M | -36.40 | ― | ― | ― | ― | |
45 Neutral | $2.96M | -0.06 | -215.04% | ― | -100.00% | 93.82% | |
44 Neutral | $2.26M | -0.11 | -203.36% | ― | ― | 90.53% | |
43 Neutral | $818.36K | -0.07 | ― | ― | 178.82% | -4121.10% | |
43 Neutral | $8.66M | -1.49 | -79.47% | ― | -99.97% | 35.59% | |
40 Underperform | $3.85M | -0.07 | ― | ― | -41.05% | 57.35% |
Turn Therapeutics Inc Corporate Events
On January 12, 2026, Turn Therapeutics issued a series of corporate, pipeline, and financial updates ahead of its participation in the J.P. Morgan Healthcare Conference, highlighting steady clinical progress and a stronger governance and capital structure. The company reported that its Phase 2 randomized controlled trial of lead asset GX-03 in moderate-to-severe atopic dermatitis remained on schedule, with both interim and topline data expected in the first half of 2026, while enrollment continued in line with statistical plans. Governance was bolstered by the appointment of seasoned life sciences and M&A executive Martin Dewhurst to the board, and the company engaged Damouni Group to refine corporate strategy, capital markets positioning, and investor communications, with an emphasis on GX-03 as a late-stage clinical asset. Turn also expanded its vaccine pipeline by adding a proprietary intranasal influenza candidate designed to deliver a thermostable, oil-based formulation targeting epithelial receptors to stimulate systemic immunity without adjuvants, with in vivo and in vitro studies planned to begin in the first quarter of 2026, broadening its addressable market beyond dermatology and wound care. On the commercial front, management flagged progress in its strategic wound care partnership with Medline, which is expected to start generating revenue in 2026 and enhance the company’s presence in advanced wound care channels. Financially, Turn utilized an existing share purchase agreement to reinforce its balance sheet and, together with existing cash reserves, extended its operating runway into late 2026, supporting continued execution of clinical, commercial, and strategic initiatives during what management characterized as a pivotal year for the company.
The most recent analyst rating on (TTRX) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Turn Therapeutics Inc stock, see the TTRX Stock Forecast page.
On January 7, 2026, Turn Therapeutics Inc. expanded its board from five to six members and appointed veteran healthcare executive Martin Dewhurst as an independent Class III director and chair of the compensation committee, with his term running until the 2028 annual shareholders’ meeting. Dewhurst, who received an initial $100,000 restricted stock unit grant under the company’s 2025 Omnibus Incentive Plan, brings more than three decades of global life sciences and M&A experience from senior roles at McKinsey & Company and ongoing advisory and board positions across healthcare and investment firms, a profile that aligns with Turn Therapeutics’ disciplined, M&A-focused growth strategy and is expected to strengthen its capital allocation, pipeline expansion and partnership efforts; the company simultaneously released a press announcement and updated investor presentation on the same date.
The most recent analyst rating on (TTRX) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Turn Therapeutics Inc stock, see the TTRX Stock Forecast page.
On November 11, 2025, Turn Therapeutics announced that its GX-03 technology was recognized by Patient Care Online Magazine as one of the ‘Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment.’ This recognition highlights the company’s innovative approach in dermatology, particularly with its topical IL36/IL31 inhibitor, which targets key inflammatory pathways in eczema and psoriasis. The announcement underscores Turn Therapeutics’ commitment to advancing its proprietary therapeutics pipeline, with plans to release topline data from its severe eczema program in early 2026.
On November 4, 2025, Turn Therapeutics announced the appointment of Andrew Scott as Vice President of Corporate Communications. This strategic hire comes as the company, following its public listing, aims to enhance investor relations and expand its market presence, with Scott’s extensive experience expected to guide the company through upcoming milestones, including the completion of its Phase 2 clinical program.
On October 30, 2025, Turn Therapeutics announced a global supply, development, and license agreement with Medline, a leading medical-surgical product manufacturer and distributor. This collaboration aims to leverage Turn’s PermaFusion® delivery platform with Medline’s global distribution capabilities to enhance product opportunities in professional and retail markets. The partnership is seen as a transformative milestone for Turn, enabling the company to focus on innovation while utilizing Medline’s infrastructure to deliver advanced solutions worldwide. Financial terms and development timelines remain confidential, with further updates expected as joint initiatives progress.
On October 27, 2025, Turn Therapeutics, Inc. entered into a Global Supply, Development, and License Agreement with Medline Industries, LP. This collaboration aims to develop, manufacture, and commercialize health products leveraging Turn’s PermaFusion® platform, with Medline handling global distribution across over 100 countries. The agreement outlines a multi-year framework for co-development and manufacturing scale-up, with an initial term of three years and automatic renewals, potentially enhancing Turn’s market reach and operational capabilities.
On October 22, 2025, Turn Therapeutics provided a shareholder update, highlighting progress in its clinical programs and its strategic capital strategy. The company is advancing its phase 2 trial of GX-03 for eczema and developing a thermostable intranasal vaccine. Turn’s direct listing structure and $85 million GEM Global Yield agreement offer flexible financing, potentially reducing future equity offerings.